Cancer surveillance strategies in ulcerative colitis: The need for modernization

Inflammatory Bowel Diseases

Volumn 17, Issue 8, 2011, Pages 1800-1813

  Efthymiou, Marios ^a,b   Taylor, Andrew C F ^a   Kamm, Michael A ^a,b,c  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

chromoendoscopy; colorectal cancer; dysplasia; ulcerative colitis

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; AZATHIOPRINE; BETA CATENIN; DNA; FOLIC ACID; MESALAZINE; METALLOTHIONEIN; PROTEIN P53; SIALOSYL TN ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

ABERRANT CRYPT FOCUS; ANEUPLOIDY; AUTOFLUORESCENCE IMAGING; BASEMENT MEMBRANE; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER PATIENT; CANCER PREVENTION; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOPROPHYLAXIS; CHROMOENDOSCOPY; CHROMOSOME ABERRATION; COLON ADENOCARCINOMA; COLON ADENOMA; COLON CARCINOGENESIS; COLON POLYP; COLON RESECTION; COLONOSCOPY; COLORECTAL CANCER; COLORECTAL POLYP; CONFOCAL MICROSCOPY; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; CYTOLOGY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DYSPLASIA; ENDOSCOPIC MUCOSAL RESECTION; ENDOSCOPIC SUBMUCOSAL DISSECTION; FAMILY HISTORY; FERTILITY; FLOW CYTOMETRY; GENOMIC INSTABILITY; HIGH GRADE DYSPLASIA; HUMAN; ILEITIS; INTERMETHOD COMPARISON; INTESTINE BIOPSY; LAMINA PROPRIA; LIFE EXPECTANCY; LIVER TRANSPLANTATION; LOW GRADE DYSPLASIA; LOW GRADE TUBULOGLANDULAR ADENOCARCINOMA; MAGNIFYING ENDOSCOPY; META ANALYSIS (TOPIC); MICROSATELLITE INSTABILITY; NARROW BAND IMAGING; NONHUMAN; POLYPECTOMY; POSTOPERATIVE HEMORRHAGE; PRACTICE GUIDELINE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROCTITIS; PROCTOCOLECTOMY; PROTEIN EXPRESSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEXUAL DYSFUNCTION; TUMOR SUPPRESSOR GENE; ULCERATIVE COLITIS; WHITE LIGHT ENDOSCOPY;

BIOLOGICAL MARKERS; BIOPSY; COLITIS, ULCERATIVE; COLONOSCOPY; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; HUMANS; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS;

EID: 79960272300     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21540     Document Type: Review

References (152)

1. Ekbom A, Helmick C, Zack M, et al. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990; 323: 1228-1233. (Pubitemid 20366527)
2. Bernstein CN, Blanchard JF, Kliewer E, et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001; 91: 854-862. (Pubitemid 32173312)
3. Eaden JA, Abrams KR, Mayberry JF,. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001; 48: 526-535. (Pubitemid 32234798)
4. Winther KV, Jess T, Langholz E, et al. Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol. 2004; 2: 1088-1095. (Pubitemid 40037640)
5. Jess T, Loftus EV Jr, Velayos FS, et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. Gastroenterology. 2006; 130: 1039-1046.
6. Rutter MD, Saunders BP, Wilkinson KH, et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology. 2006; 130: 1030-1038.
7. Loftus EV Jr,. Epidemiology and risk factors for colorectal dysplasia and cancer in ulcerative colitis. Gastroenterol Clin North Am. 2006; 35: 517-531. (Pubitemid 44307577)
8. Stolfi C, Pellegrini R, Franze E, et al. Molecular basis of the potential of mesalazine to prevent colorectal cancer. World J Gastroenterol. 2008; 14: 4434-4439.
9. van Staa TP, Card T, Logan RF, et al. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut. 2005; 54: 1573-1578. (Pubitemid 41531774)
10. Eaden J, Abrams K, Ekbom A, et al. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther. 2000; 14: 145-153. (Pubitemid 30088290)
11. Beaugerie L, Seksik P, Bouvier A, et al. Thiopurine therapy is associated with a three-fold decrease in the incidence of advanced colorectal neoplasia in IBD patients with longstanding extensive colitis: results from the CESAME Cohort. Digestive Disease Week, Chicago; 2009: 281. Abstract.
12. Langholz E, Munkholm P, Davidsen M, et al. Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology. 1992; 103: 1444-1451.
13. Gyde SN, Prior P, Allan RN, et al. Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centres. Gut. 1988; 29: 206-217. (Pubitemid 18078890)
14. Prior P, Gyde SN, Macartney JC, et al. Cancer morbidity in ulcerative colitis. Gut. 1982; 23: 490-497. (Pubitemid 12119347)
15. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004; 126: 451-459. (Pubitemid 38182302)
16. Velayos FS, Loftus EV Jr, Jess T, et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology. 2006; 130: 1941-1949. (Pubitemid 43816957)
17. Gumaste V, Sachar DB, Greenstein AJ,. Benign and malignant colorectal strictures in ulcerative colitis. Gut. 1992; 33: 938-941.
18. Reiser JR, Waye JD, Janowitz HD, et al. Adenocarcinoma in strictures of ulcerative colitis without antecedent dysplasia by colonoscopy. Am J Gastroenterol. 1994; 89: 119-122. (Pubitemid 24020066)
19. Nuako KW, Ahlquist DA, Mahoney DW, et al. Familial predisposition for colorectal cancer in chronic ulcerative colitis: a case-control study. Gastroenterology. 1998; 115: 1079-1083. (Pubitemid 28485597)
20. Askling J, Dickman PW, Karlen P, et al. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology. 2001; 120: 1356-1362. (Pubitemid 32322309)
21. Soetikno RM, Lin OS, Heidenreich PA, et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc. 2002; 56: 48-54. (Pubitemid 41115048)
22. Broome U, Lofberg R, Veress B, et al. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology. 1995; 22: 1404-1408.
23. Marchesa P, Lashner BA, Lavery IC, et al. The risk of cancer and dysplasia among ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol. 1997; 92: 1285-1288. (Pubitemid 27328584)
24. Lindberg BU, Broome U, Persson B,. Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine: results from a 20-year surveillance study. Dis Colon Rectum. 2001; 44: 77-85. (Pubitemid 32105878)
25. Riddell RH, Goldman H, Ransohoff DF, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol. 1983; 14: 931-968.
26. Lim CH, Dixon MF, Vail A, et al. Ten year follow up of ulcerative colitis patients with and without low grade dysplasia. Gut. 2003; 52: 1127-1132. (Pubitemid 36877424)
27. Eaden J, Abrams K, McKay H, et al. Inter-observer variation between general and specialist gastrointestinal pathologists when grading dysplasia in ulcerative colitis. J Pathol. 2001; 194: 152-157. (Pubitemid 32519963)
28. Riddell RH,. Grading of dysplasia. Eur J Cancer. 1995; 31A: 1169-1170.
29. McKenna BJ, Appelman HD,. Dysplasia can be a pain in the gut. Pathology. 2002; 34: 518-528. (Pubitemid 36026726)
30. Fogt F, Urbanski SJ, Sanders ME, et al. Distinction between dysplasia-associated lesion or mass (DALM) and adenoma in patients with ulcerative colitis. Hum Pathol. 2000; 31: 288-291. (Pubitemid 30161345)
31. Allen PB, Cruz PD, Kamm MA,. Dysplastic lesions in ulcerative colitis: changing paradigms. Inflamm Bowel Dis. 2010 [Epub ahead of print].
32. Woolrich AJ, DaSilva MD, Korelitz BI,. Surveillance in the routine management of ulcerative colitis: the predictive value of low-grade dysplasia. Gastroenterology. 1992; 103: 431-438.
33. Thomas T, Abrams KA, Robinson RJ, et al. Meta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis. Aliment Pharmacol Ther. 2007; 25: 657-668.
34. Jess T, Loftus EV Jr, Velayos FS, et al. Incidence and prognosis of colorectal dysplasia in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. Inflamm Bowel Dis. 2006; 12: 669-676. (Pubitemid 44253749)
35. Bernstein CN, Shanahan F, Weinstein WM,. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet. 1994; 343: 71-74. (Pubitemid 24019346)
36. Ullman T, Croog V, Harpaz N, et al. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology. 2003; 125: 1311-1319. (Pubitemid 37409751)
37. Levi GS, Harpaz N,. Intestinal low-grade tubuloglandular adenocarcinoma in inflammatory bowel disease. Am J Surg Pathol. 2006; 30: 1022-1029. (Pubitemid 44264953)
38. Lennard-Jones JE, Morson BC, Ritchie JK, et al. Cancer in colitis: assessment of the individual risk by clinical and histological criteria. Gastroenterology. 1977; 73: 1280-1289. (Pubitemid 8229277)
39. Fuson JA, Farmer RG, Hawk A, et al. Endoscopic surveillance for cancer in chronic ulcerative colitis. Am J Gastroenterol. 1980; 73: 120-126. (Pubitemid 10083209)
40. Kewenter J, Hulten L, Ahren C,. The occurrence of severe epithelial dysplasia and its bearing on treatment of longstanding ulcerative colitis. Ann Surg. 1982; 195: 209-213. (Pubitemid 12222885)
41. Rosenstock E, Farmer RG, Petras R, et al. Surveillance for colonic carcinoma in ulcerative colitis. Gastroenterology. 1985; 89: 1342-1346. (Pubitemid 16228058)
42. Nugent FW, Haggitt RC, Gilpin PA,. Cancer surveillance in ulcerative colitis. Gastroenterology. 1991; 100: 1241-1248.
43. Taylor BA, Pemberton JH, Carpenter HA, et al. Dysplasia in chronic ulcerative colitis: implications for colonoscopic surveillance. Dis Colon Rectum. 1992; 35: 950-956.
44. Connell WR, Talbot IC, Harpaz N, et al. Clinicopathological characteristics of colorectal carcinoma complicating ulcerative colitis. Gut. 1994; 35: 1419-1423. (Pubitemid 24310904)
45. Rosman-Urbach M, Niv Y, Birk Y, et al. A high degree of aneuploidy, loss of p53 gene, and low soluble p53 protein serum levels are detected in ulcerative colitis patients. Dis Colon Rectum. 2004; 47: 304-313. (Pubitemid 38280582)
46. Bruewer M, Schmid KW, Krieglstein CF, et al. Metallothionein: early marker in the carcinogenesis of ulcerative colitis-associated colorectal carcinoma. World J Surg. 2002; 26: 726-731. (Pubitemid 36920350)
47. Willenbucher RF, Aust DE, Chang CG, et al. Genomic instability is an early event during the progression pathway of ulcerative-colitis-related neoplasia. Am J Pathol. 1999; 154: 1825-1830. (Pubitemid 29262864)
48. Fujiwara I, Yashiro M, Kubo N, et al. Ulcerative colitis-associated colorectal cancer is frequently associated with the microsatellite instability pathway. Dis Colon Rectum. 2008; 51: 1387-1394.
49. Kukitsu T, Takayama T, Miyanishi K, et al. Aberrant crypt foci as precursors of the dysplasia-carcinoma sequence in patients with ulcerative colitis. Clin Cancer Res. 2008; 14: 48-54. (Pubitemid 351377977)
50. Connell WR, Lennard-Jones JE, Williams CB, et al. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology. 1994; 107: 934-944. (Pubitemid 24294554)
51. Choi PM, Nugent FW, Schoetz DJ Jr, et al. Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis. Gastroenterology. 1993; 105: 418-424. (Pubitemid 23213526)
52. Lynch DA, Lobo AJ, Sobala GM, et al. Failure of colonoscopic surveillance in ulcerative colitis. Gut. 1993; 34: 1075-1080. (Pubitemid 23245358)
53. Collins PD, Mpofu C, Watson AJ, et al. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev. 2006: CD000279.
54. Itzkowitz SH, Present DH,. Consensus conference: colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis. 2005; 11: 314-321. (Pubitemid 40439686)
55. Petritsch W, Tillinger W, Vogelsang H, et al. [Endoscopy in IBD. A consensus report of the IBD Working of the Austrian Association of Gastroenterology and Hepatology.] Z Gastroenterol. 2006; 44: 1183-1192. (Pubitemid 44900209)
56. Eaden JA, Mayberry JF,. Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut. 2002; 51 (suppl 5): V10-12. (Pubitemid 35222898)
57. Rubin DT, Kavitt RT,. Surveillance for cancer and dysplasia in inflammatory bowel disease. Gastroenterol Clin North Am. 2006; 35: 581-604. (Pubitemid 44307574)
58. Carter MJ, Lobo AJ, Travis SP,. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004; 53 (suppl 5): V1-16. (Pubitemid 39120096)
59. Farraye FA, Odze RD, Eaden J, et al. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010; 138: 746-774, 774 e741- 744, quiz e712-743.
60. Farraye FA, Odze RD, Eaden J, et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010; 138: 738-745.
61. Itzkowitz SH, Harpaz N,. Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology. 2004; 126: 1634-1648. (Pubitemid 38649879)
62. Rubin CE, Haggitt RC, Burmer GC, et al. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology. 1992; 103: 1611-1620.
63. Rutter MD, Saunders BP, Schofield G, et al. Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis. Gut. 2004; 53: 256-260. (Pubitemid 38125515)
64. Hurlstone DP, Sanders DS, Lobo AJ, et al. Indigo carmine-assisted high-magnification chromoscopic colonoscopy for the detection and characterisation of intraepithelial neoplasia in ulcerative colitis: a prospective evaluation. Endoscopy. 2005; 37: 1186-1192. (Pubitemid 41763534)
65. Bernstein CN, Weinstein WM, Levine DS, et al. Physicians' perceptions of dysplasia and approaches to surveillance colonoscopy in ulcerative colitis. Am J Gastroenterol. 1995; 90: 2106-2114.
66. Eaden JA, Ward BA, Mayberry JF,. How gastroenterologists screen for colonic cancer in ulcerative colitis: an analysis of performance. Gastrointest Endosc. 2000; 51: 123-128. (Pubitemid 30094501)
67. van Rijn AF, Fockens P, Siersema PD, et al. Adherence to surveillance guidelines for dysplasia and colorectal carcinoma in ulcerative and Crohn's colitis patients in the Netherlands. World J Gastroenterol. 2009; 15: 226-230.
68. Rutter MD, Saunders BP, Wilkinson KH, et al. Most dysplasia in ulcerative colitis is visible at colonoscopy. Gastrointest Endosc. 2004; 60: 334-339. (Pubitemid 39164238)
69. Rubin DT, Rothe JA, Hetzel JT, et al. Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis? Gastrointest Endosc. 2007; 65: 998-1004. (Pubitemid 46770732)
70. Blonski W, Kundu R, Lewis J, et al. Is dysplasia visible during surveillance colonoscopy in patients with ulcerative colitis? Scand J Gastroenterol. 2008; 43: 698-703. (Pubitemid 351868711)
71. Anandasabapathy S,. Endoscopic imaging: emerging optical techniques for the detection of colorectal neoplasia. Curr Opin Gastroenterol. 2008; 24: 64-69. (Pubitemid 350190900)
72. Hardie LJ, Olliver JR, Wild CP, et al. Chromoendoscopy with methylene blue and the risk of DNA damage. Gastroenterology. 2004; 126: 623; author reply 623- 624.
73. Olliver JR, Wild CP, Sahay P, et al. Chromoendoscopy with methylene blue and associated DNA damage in Barrett's oesophagus. Lancet. 2003; 362: 373-374. (Pubitemid 36945061)
74. Kiesslich R, Fritsch J, Holtmann M, et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology. 2003; 124: 880-888. (Pubitemid 36389789)
75. Marion JF, Waye JD, Present DH, et al. Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial. Am J Gastroenterol. 2008; 103: 2342-2349.
76. East JE, Suzuki N, Bassett P, et al. Narrow band imaging with magnification for the characterization of small and diminutive colonic polyps: pit pattern and vascular pattern intensity. Endoscopy. 2008; 40: 811-817.
77. East JE, Suzuki N, Saunders BP,. Comparison of magnified pit pattern interpretation with narrow band imaging versus chromoendoscopy for diminutive colonic polyps: a pilot study. Gastrointest Endosc. 2007; 66: 310-316. (Pubitemid 47069295)
78. Matsumoto T, Kudo T, Jo Y, et al. Magnifying colonoscopy with narrow band imaging system for the diagnosis of dysplasia in ulcerative colitis: a pilot study. Gastrointest Endosc. 2007; 66: 957-965. (Pubitemid 47600174)
79. Dekker E, van den Broek FJ, Reitsma JB, et al. Narrow-band imaging compared with conventional colonoscopy for the detection of dysplasia in patients with longstanding ulcerative colitis. Endoscopy. 2007; 39: 216-221. (Pubitemid 46510792)
80. Ginsberg GG, Kochman ML, Norton I, et al (eds.). Clinical gastrointestinal endoscopy, 1st ed. Amsterdam: Elsevier Saunders; 2005.
81. McCallum AL, Jenkins JT, Gillen D, et al. Evaluation of autofluorescence colonoscopy for the detection and diagnosis of colonic polyps. Gastrointest Endosc. 2008; 68: 283-290.
82. Matsumoto T, Moriyama T, Yao T, et al. Autofluorescence imaging colonoscopy for the diagnosis of dysplasia in ulcerative colitis. Inflamm Bowel Dis. 2007; 13: 640-641. (Pubitemid 46799649)
83. van den Broek FJ, Fockens P, van Eeden S, et al. Endoscopic tri-modal imaging for surveillance in ulcerative colitis: randomised comparison of high-resolution endoscopy and autofluorescence imaging for neoplasia detection; and evaluation of narrow-band imaging for classification of lesions. Gut. 2008; 57: 1083-1089.
84. Kudo S, Hirota S, Nakajima T, et al. Colorectal tumours and pit pattern. J Clin Pathol. 1994; 47: 880-885.
85. Liu HH, Kudo SE, Juch JP,. Pit pattern analysis by magnifying chromoendoscopy for the diagnosis of colorectal polyps. J Formos Med Assoc. 2003; 102: 178-182.
86. Kato S, Fu KI, Sano Y, et al. Magnifying colonoscopy as a non-biopsy technique for differential diagnosis of non-neoplastic and neoplastic lesions. World J Gastroenterol. 2006; 12: 1416-1420.
87. Fu KI, Sano Y, Kato S, et al. Chromoendoscopy using indigo carmine dye spraying with magnifying observation is the most reliable method for differential diagnosis between non-neoplastic and neoplastic colorectal lesions: a prospective study. Endoscopy. 2004; 36: 1089-1093. (Pubitemid 39642470)
88. Hata K, Watanabe T, Motoi T, et al. Pitfalls of pit pattern diagnosis in ulcerative colitis-associated dysplasia. Gastroenterology. 2004; 126: 374-376. (Pubitemid 38040755)
89. Kiesslich R, Burg J, Vieth M, et al. Confocal laser endoscopy for diagnosing intraepithelial neoplasias and colorectal cancer in vivo. Gastroenterology. 2004; 127: 706-713. (Pubitemid 39208403)
90. Hurlstone DP, Thomson M, Brown S, et al. Confocal endomicroscopy in ulcerative colitis: differentiating dysplasia-associated lesional mass and adenoma-like mass. Clin Gastroenterol Hepatol. 2007; 5: 1235-1241. (Pubitemid 47488965)
91. Kiesslich R, Goetz M, Lammersdorf K, et al. Chromoscopy-guided endomicroscopy increases the diagnostic yield of intraepithelial neoplasia in ulcerative colitis. Gastroenterology. 2007; 132: 874-882. (Pubitemid 46440874)
92. Marvik R, Lango T,. High-definition television in medicine. Surg Endosc. 2006; 20: 349-350. (Pubitemid 43260488)
93. Shastri Y, Loitsch S, Dignass A, et al. Prospective evaluation of fecal congranulin a in IBD based on a new immuno assay. Digestive Disease Week, Chicago; 2009. Abstract.
94. Kanmura S, Uto H, Numata M, et al. Human neutrophil peptides 1-3 are useful biomarkers in patients with active ulcerative colitis. Inflamm Bowel Dis. 2009; 15: 909-917.
95. Talero E, Sánchez-Fidalgo S, Villegas I, et al. In vivo characterization of biomarkers associated with experimental chronic inflammation and colon cancer. Participation of adrenomedullin. Digestive Disease Week, Chicago; 2009.
96. Itzkowitz SH, Marshall A, Kornbluth A, et al. Sialosyl-Tn antigen: initial report of a new marker of malignant progression in long-standing ulcerative colitis. Gastroenterology. 1995; 109: 490-497.
97. Hammarberg C, Rubio C, Slezak P, et al. Flow-cytometric DNA analysis as a means for early detection of malignancy in patients with chronic ulcerative colitis. Gut. 1984; 25: 905-908. (Pubitemid 14053541)
98. Hammarberg C, Slezak P, Tribukait B,. Early detection of malignancy in ulcerative colitis. A flow-cytometric DNA study. Cancer. 1984; 53: 291-295. (Pubitemid 14180743)
99. Keller R, Foerster EC, Kohler A, et al. Diagnostic value of DNA image cytometry in ulcerative colitis. Dig Dis Sci. 2001; 46: 870-878. (Pubitemid 32373110)
100. Befrits R, Hammarberg C, Rubio C, et al. DNA aneuploidy and histologic dysplasia in long-standing ulcerative colitis. A 10-year follow-up study. Dis Colon Rectum. 1994; 37: 313-319; discussion 319-320.
101. Sjoqvist U, Befrits R, Soderlund S, et al. Colorectal cancer in colonic Crohn's disease-high frequency of DNA-aneuploidy. Anticancer Res. 2005; 25: 4393-4397. (Pubitemid 41729484)
102. Keller R, Brandt B, Terpe HJ, et al. Cytology and image cytometry after colonic lavage: a complementary diagnostic tool in patients with ulcerative colitis. Dig Liver Dis. 2003; 35: 24-31. (Pubitemid 36546659)
103. Pinczowski D, Ekbom A, Baron J, et al. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology. 1994; 107: 117-120. (Pubitemid 24195353)
104. Bernstein CN, Blanchard JF, Metge C, et al. Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer? Am J Gastroenterol. 2003; 98: 2784-2788. (Pubitemid 38020124)
105. Velayos FS, Terdiman JP, Walsh JM,. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol. 2005; 100: 1345-1353. (Pubitemid 40904360)
106. Lashner BA, Heidenreich PA, Su GL, et al. Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis. A case-control study. Gastroenterology. 1989; 97: 255-259. (Pubitemid 19192158)
107. Lashner BA,. Red blood cell folate is associated with the development of dysplasia and cancer in ulcerative colitis. J Cancer Res Clin Oncol. 1993; 119: 549-554. (Pubitemid 23180046)
108. Pardi DS, Loftus EV Jr, Kremers WK, et al. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology. 2003; 124: 889-893. (Pubitemid 36389790)
109. Provenzale D, Kowdley KV, Arora S, et al. Prophylactic colectomy or surveillance for chronic ulcerative colitis? A decision analysis. Gastroenterology. 1995; 109: 1188-1196.
110. Spiegel BM, Ho W, Esrailian E, et al. Controversies in ulcerative colitis: a survey comparing decision making of experts versus community gastroenterologists. Clin Gastroenterol Hepatol. 2009; 7: 168-174, 174 e161.
111. Rodriguez SA, Collins JM, Knigge KL, et al. Surveillance and management of dysplasia in ulcerative colitis. Gastrointest Endosc. 2007; 65: 432-439.
112. Kaltz B, Bokemeyer B, Hoffmann J, et al. [Surveillance colonoscopy in ulcerative colitis patients in Germany.] Z Gastroenterol. 2007; 45: 325-331. (Pubitemid 46739980)
113. Reddy SI, Friedman S, Telford JJ, et al. Are patients with inflammatory bowel disease receiving optimal care? Am J Gastroenterol. 2005; 100: 1357-1361. (Pubitemid 40904362)
114. Thomas T, Nair P, Dronfield MW, et al. Management of low and high-grade dysplasia in inflammatory bowel disease: the gastroenterologists' perspective and current practice in the United Kingdom. Eur J Gastroenterol Hepatol. 2005; 17: 1317-1324. (Pubitemid 41830452)
115. Nguyen GC, Frick KD, Dassopoulos T,. Medical decision analysis for the management of unifocal, flat, low-grade dysplasia in ulcerative colitis. Gastrointest Endosc. 2009; 69: 1299-1310.
116. Blackstone MO, Riddell RH, Rogers BH, et al. Dysplasia-associated lesion or mass (DALM) detected by colonoscopy in long-standing ulcerative colitis: an indication for colectomy. Gastroenterology. 1981; 80: 366-374. (Pubitemid 11217532)
117. Medlicott SA, Jewell LD, Price L, et al. Conservative management of small adenomata in ulcerative colitis. Am J Gastroenterol. 1997; 92: 2094-2098. (Pubitemid 27476258)
118. Torres C, Antonioli D, Odze RD,. Polypoid dysplasia and adenomas in inflammatory bowel disease: a clinical, pathologic, and follow-up study of 89 polyps from 59 patients. Am J Surg Pathol. 1998; 22: 275-284. (Pubitemid 28108408)
119. Rubin PH, Friedman S, Harpaz N, et al. Colonoscopic polypectomy in chronic colitis: conservative management after endoscopic resection of dysplastic polyps. Gastroenterology. 1999; 117: 1295-1300.
120. Hurlstone DP, Sanders DS, Atkinson R, et al. Endoscopic mucosal resection for flat neoplasia in chronic ulcerative colitis: can we change the endoscopic management paradigm? Gut. 2007; 56: 838-846. (Pubitemid 46854201)
121. Engelsgjerd M, Farraye FA, Odze RD,. Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis. Gastroenterology. 1999; 117: 1288-1294; discussion 1488-1291.
122. Odze RD, Farraye FA, Hecht JL, et al. Long-term follow-up after polypectomy treatment for adenoma-like dysplastic lesions in ulcerative colitis. Clin Gastroenterol Hepatol. 2004; 2: 534-541. (Pubitemid 38834037)
123. Vieth M, Behrens H, Stolte M,. Sporadic adenoma in ulcerative colitis: endoscopic resection is an adequate treatment. Gut. 2006; 55: 1151-1155. (Pubitemid 44085684)
124. Blonski W, Kundu R, Furth EF, et al. High-grade dysplastic adenoma-like mass lesions are not an indication for colectomy in patients with ulcerative colitis. Scand J Gastroenterol. 2008; 43: 817-820. (Pubitemid 351918512)
125. Pech O, Behrens A, May A, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. Gut. 2008; 57: 1200-1206.
126. Smith LA, Baraza W, Tiffin N, et al. Endoscopic resection of adenoma-like mass in chronic ulcerative colitis using a combined endoscopic mucosal resection and cap assisted submucosal dissection technique. Inflamm Bowel Dis. 2008; 14: 1380-1386.
127. Ouaissi M, Lefevre JH, Bretagnol F, et al. Laparoscopic 3-step restorative proctocolectomy: comparative study with open approach in 45 patients. Surg Laparosc Endosc Percutan Tech. 2008; 18: 357-362.
128. Heise CP, Kennedy G, Foley EF, et al. Laparoscopic restorative proctocolectomy with ileal S-pouch. Dis Colon Rectum. 2008; 51: 1790-1794.
129. Zhang H, Hu S, Zhi X, et al. Laparoscopic proctocolectomy with ileal pouch-anal anastomosis. Surg Laparosc Endosc Percutan Tech. 2007; 17: 388-391. (Pubitemid 351339208)
130. Hahnloser D, Pemberton JH, Wolff BG, et al. Results at up to 20 years after ileal pouch-anal anastomosis for chronic ulcerative colitis. Br J Surg. 2007; 94: 333-340. (Pubitemid 46423852)
131. Walker LR, Bulow S,. [Restorative proctocolectomy with an ileoanal pouch. Postoperative course and long-term functional results.] Ugeskr Laeger. 2008; 170: 1721-1725.
132. Ferrante M, Declerck S, De Hertogh G, et al. Outcome after proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis. Inflamm Bowel Dis. 2008; 14: 20-28. (Pubitemid 351196864)
133. Cornish JA, Tan E, Teare J, et al. The effect of restorative proctocolectomy on sexual function, urinary function, fertility, pregnancy and delivery: a systematic review. Dis Colon Rectum. 2007; 50: 1128-1138. (Pubitemid 47087474)
134. Stern H, Walfisch S, Mullen B, et al. Cancer in an ileoanal reservoir: a new late complication? Gut. 1990; 31: 473-475. (Pubitemid 20129451)
135. Hassan C, Zullo A, Speziale G, et al. Adenocarcinoma of the ileoanal pouch anastomosis: an emerging complication? Int J Colorectal Dis. 2003; 18: 276-278. (Pubitemid 36764177)
136. Coull DB, Lee FD, Henderson AP, et al. Risk of dysplasia in the columnar cuff after stapled restorative proctocolectomy. Br J Surg. 2003; 90: 72-75. (Pubitemid 37040974)
137. Ziv Y, Fazio VW, Sirimarco MT, et al. Incidence, risk factors, and treatment of dysplasia in the anal transitional zone after ileal pouch-anal anastomosis. Dis Colon Rectum. 1994; 37: 1281-1285.
138. O'Riordain MG, Fazio VW, Lavery IC, et al. Incidence and natural history of dysplasia of the anal transitional zone after ileal pouch-anal anastomosis: results of a five-year to ten-year follow-up. Dis Colon Rectum. 2000; 43: 1660-1665. (Pubitemid 32001862)
139. Remzi FH, Fazio VW, Delaney CP, et al. Dysplasia of the anal transitional zone after ileal pouch-anal anastomosis: results of prospective evaluation after a minimum of ten years. Dis Colon Rectum. 2003; 46: 6-13. (Pubitemid 36105824)
140. Hyman N,. Rectal cancer as a complication of stapled IPAA. Inflamm Bowel Dis. 2002; 8: 43-45. (Pubitemid 34126710)
141. Bentrem DJ, Wang KL, Stryker SJ,. Adenocarcinoma in an ileal pouch occurring 14 years after restorative proctocolectomy: report of a case. Dis Colon Rectum. 2003; 46: 544-546. (Pubitemid 36428054)
142. Stahlberg D, Veress B, Tribukait B, et al. Atrophy and neoplastic transformation of the ileal pouch mucosa in patients with ulcerative colitis and primary sclerosing cholangitis: a case control study. Dis Colon Rectum. 2003; 46: 770-778. (Pubitemid 36693397)
143. Gullberg K, Lindforss U, Zetterquist H, et al. Cancer risk assessment in long-standing pouchitis. DNA aberrations are rare in transformed neoplastic pelvic pouch mucosa. Int J Colorectal Dis. 2002; 17: 92-97. (Pubitemid 36067754)
144. Das P, Johnson MW, Tekkis PP, et al. Risk of dysplasia and adenocarcinoma following restorative proctocolectomy for ulcerative colitis. Colorectal Dis. 2007; 9: 15-27. (Pubitemid 44869672)
145. Johnson WR, McDermott FT, Pihl E, et al. Mucosal dysplasia. A major predictor of cancer following ileorectal anastomosis. Dis Colon Rectum. 1983; 26: 697-700. (Pubitemid 13013671)
146. Filipe MI, Edwards MR, Ehsanullah M,. A prospective study of dysplasia and carcinoma in the rectal biopsies and rectal stump of eight patients following ileorectal anastomosis in ulcerative colitis. Histopathology. 1985; 9: 1139-1153. (Pubitemid 16213207)
147. Thomas DM, Filipe MI, Smedley FH,. Dysplasia and carcinoma in the rectal stump of total colitics who have undergone colectomy and ileo-rectal anastomosis. Histopathology. 1989; 14: 289-298. (Pubitemid 19084756)
148. McLaughlin SD, Clark SK, Tekkis PP, et al. Review article: restorative proctocolectomy, indications, management of complications and follow-up-a guide for gastroenterologists. Aliment Pharmacol Ther. 2008; 27: 895-909. (Pubitemid 351537645)
149. Gillen CD, Walmsley RS, Prior P, et al. Ulcerative colitis and Crohn's disease: a comparison of the colorectal cancer risk in extensive colitis. Gut. 1994; 35: 1590-1592. (Pubitemid 24339258)
150. Friedman S, Rubin PH, Bodian C, et al. Screening and surveillance colonoscopy in chronic Crohn's colitis: results of a surveillance program spanning 25 years. Clin Gastroenterol Hepatol. 2008; 6: 993-998; quiz 953-994.
151. Sanaka MR, Shah N, Mullen KD, et al. Afternoon colonoscopies have higher failure rates than morning colonoscopies. Am J Gastroenterol. 2006; 101: 2726-2730. (Pubitemid 44902643)
152. Wells CD, Heigh RI, Sharma VK, et al. Comparison of morning versus afternoon cecal intubation rates. BMC Gastroenterol. 2007; 7: 19.